Aclaris Therapeutics
ACRS | NASDAQ
$3.60
-$0.32 (-8.16%)
At close: Nov 16, 2026, 4:00 PM ET
$3.66
+$0.06 (+1.66%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-8.16%
(1D)No price chart data available for 1D timeframe.
Rating
32.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #720/1021 (Top 71%)
Key Statistics
Market Data
Market Cap $571.8M
1D Range
3.31 3.70
52W Range
2.41 6.54
Valuation (TTM)
PE -6.21
PB 3.43
EV/EBITDA -5.57
Valuation (NTM)
Forward PE N/A
Forward PEG -0.47
Price Target $9.50
Cash Flow
FCF Yield -13.2%
SBC Adj. FCF Yield -15.2%
SBC Impact -15.7%
Margins
Gross Margin 99.8%
Operating Margin -1414.0%
FCF Margin -1175.3%
Growth (CAGR)
Revenue 3Y | 5Y -33.2% |
-1.3%
Dil EPS 3Y | 5Y -3.6% |
14.9%
FCF 3Y | 5Y -49.1% |
-0.9%
Returns
ROA -36.8%
ROE -59.2%
ROIC -47.2%
Financial Health
Net Cash
$114.29M
Current Ratio 5.09
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inf...
Sector Healthcare
Industry Biotechnology
Employees 71
IPO Date Oct 6, 2015
Website www.aclaristx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.12
Beat +25.00%
YoY:
0.00% REV
$1.48M
Beat +16.54%
YoY:
-55.11%Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
4
Consensus
Buy
Price Target
$9.50
Upside
+163.89%
Buy (4)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ACRS